Role  ||| S:0 E:5 ||| NN
of  ||| S:5 E:8 ||| IN
the  ||| S:8 E:12 ||| DT
incretin  ||| S:12 E:21 ||| JJ
pathway  ||| S:21 E:29 ||| NN
in  ||| S:29 E:32 ||| IN
the  ||| S:32 E:36 ||| DT
pathogenesis  ||| S:36 E:49 ||| NN
of  ||| S:49 E:52 ||| IN
type  ||| S:52 E:57 ||| NN
2  ||| S:57 E:59 ||| CD
diabetes  ||| S:59 E:68 ||| FW
mellitus  ||| S:68 E:77 ||| FW
Nutrient  ||| S:77 E:86 ||| FW
intake  ||| S:86 E:93 ||| FW
stimulates  ||| S:93 E:104 ||| FW
the  ||| S:104 E:108 ||| DT
secretion  ||| S:108 E:118 ||| NN
of  ||| S:118 E:121 ||| IN
the  ||| S:121 E:125 ||| DT
gastrointestinal  ||| S:125 E:142 ||| JJ
incretin  ||| S:142 E:151 ||| JJ
hormones ||| S:151 E:159 ||| NNS
,  ||| S:159 E:161 ||| ,
glucagon-like  ||| S:161 E:175 ||| NNP
peptide-1  ||| S:175 E:185 ||| NNP
( ||| S:185 E:186 ||| -LRB-
GLP-1 ||| S:186 E:191 ||| NNP
)  ||| S:191 E:193 ||| -RRB-
and  ||| S:193 E:197 ||| CC
glucose-dependent  ||| S:197 E:215 ||| JJ
insulinotropic  ||| S:215 E:230 ||| JJ
polypeptide  ||| S:230 E:242 ||| NNS
( ||| S:242 E:243 ||| -LRB-
GIP ||| S:243 E:246 ||| NNP
) ||| S:246 E:247 ||| -RRB-
,  ||| S:247 E:249 ||| ,
which  ||| S:249 E:255 ||| WDT
exert  ||| S:255 E:261 ||| VBZ
glucose-dependent  ||| S:261 E:279 ||| JJ
insulinotropic  ||| S:279 E:294 ||| JJ
effects  ||| S:294 E:302 ||| NNS
and  ||| S:302 E:306 ||| CC
assist  ||| S:306 E:313 ||| VB
pancreatic  ||| S:313 E:324 ||| JJ
insulin  ||| S:324 E:332 ||| NN
and  ||| S:332 E:336 ||| CC
glucagon  ||| S:336 E:345 ||| NN
in  ||| S:345 E:348 ||| IN
maintaining  ||| S:348 E:360 ||| VBG
glucose  ||| S:360 E:368 ||| JJ
homeostasis ||| S:368 E:379 ||| NN
.  ||| S:379 E:381 ||| .
GLP-1  ||| S:381 E:387 ||| NNP
also  ||| S:387 E:392 ||| RB
suppresses  ||| S:392 E:403 ||| JJ
glucose-dependent  ||| S:403 E:421 ||| JJ
glucagon  ||| S:421 E:430 ||| JJ
secretion ||| S:430 E:439 ||| NN
,  ||| S:439 E:441 ||| ,
slows  ||| S:441 E:447 ||| VBZ
gastric  ||| S:447 E:455 ||| JJ
emptying ||| S:455 E:463 ||| NN
,  ||| S:463 E:465 ||| ,
increases  ||| S:465 E:475 ||| VBZ
satiety ||| S:475 E:482 ||| VBN
,  ||| S:482 E:484 ||| ,
and  ||| S:484 E:488 ||| CC
reduces  ||| S:488 E:496 ||| JJ
food  ||| S:496 E:501 ||| NN
intake ||| S:501 E:507 ||| NN
.  ||| S:507 E:509 ||| .
An  ||| S:509 E:512 ||| DT
impaired  ||| S:512 E:521 ||| JJ
incretin  ||| S:521 E:530 ||| JJ
system ||| S:530 E:536 ||| NN
,  ||| S:536 E:538 ||| ,
characterized  ||| S:538 E:552 ||| VBN
by  ||| S:552 E:555 ||| IN
decreased  ||| S:555 E:565 ||| JJ
responsiveness  ||| S:565 E:580 ||| NN
to  ||| S:580 E:583 ||| TO
GIP  ||| S:583 E:587 ||| NNP
and  ||| S:587 E:591 ||| CC
markedly  ||| S:591 E:600 ||| RB
reduced  ||| S:600 E:608 ||| VBD
GLP-1  ||| S:608 E:614 ||| CD
concentration ||| S:614 E:627 ||| NN
,  ||| S:627 E:629 ||| ,
occurs  ||| S:629 E:636 ||| VBZ
in  ||| S:636 E:639 ||| IN
individuals  ||| S:639 E:651 ||| NNS
with  ||| S:651 E:656 ||| IN
type  ||| S:656 E:661 ||| NN
2  ||| S:661 E:663 ||| CD
diabetes  ||| S:663 E:672 ||| NN
mellitus  ||| S:672 E:681 ||| NNS
( ||| S:681 E:682 ||| -LRB-
T2DM ||| S:682 E:686 ||| NNP
) ||| S:686 E:687 ||| -RRB-
.  ||| S:687 E:689 ||| .
The  ||| S:689 E:693 ||| DT
administration  ||| S:693 E:708 ||| NN
of  ||| S:708 E:711 ||| IN
GLP-1  ||| S:711 E:717 ||| NNP
improves  ||| S:717 E:726 ||| VBZ
glycemic  ||| S:726 E:735 ||| JJ
control ||| S:735 E:742 ||| NN
,  ||| S:742 E:744 ||| ,
but  ||| S:744 E:748 ||| CC
GLP-1  ||| S:748 E:754 ||| NNP
is  ||| S:754 E:757 ||| VBZ
rapidly  ||| S:757 E:765 ||| RB
degraded  ||| S:765 E:774 ||| VBN
by  ||| S:774 E:777 ||| IN
the  ||| S:777 E:781 ||| DT
enzyme  ||| S:781 E:788 ||| FW
dipeptidyl  ||| S:788 E:799 ||| FW
peptidase-4  ||| S:799 E:811 ||| FW
( ||| S:811 E:812 ||| -LRB-
DPP-4 ||| S:812 E:817 ||| NNP
) ||| S:817 E:818 ||| -RRB-
.  ||| S:818 E:820 ||| .
Exenatide ||| S:820 E:829 ||| NNP
,  ||| S:829 E:831 ||| ,
a  ||| S:831 E:833 ||| DT
DPP-4-resistant  ||| S:833 E:849 ||| FW
exendin-4  ||| S:849 E:859 ||| FW
GLP-1  ||| S:859 E:865 ||| FW
receptor  ||| S:865 E:874 ||| FW
agonist ||| S:874 E:881 ||| FW
,  ||| S:881 E:883 ||| ,
exhibits  ||| S:883 E:892 ||| VBZ
the  ||| S:892 E:896 ||| DT
glucoregulatory  ||| S:896 E:912 ||| JJ
actions  ||| S:912 E:920 ||| NNS
of  ||| S:920 E:923 ||| IN
GLP-1  ||| S:923 E:929 ||| NNP
and  ||| S:929 E:933 ||| CC
reduces  ||| S:933 E:941 ||| JJ
body  ||| S:941 E:946 ||| NN
weight  ||| S:946 E:953 ||| NN
in  ||| S:953 E:956 ||| IN
patients  ||| S:956 E:965 ||| NNS
with  ||| S:965 E:970 ||| IN
T2DM ||| S:970 E:974 ||| CD
.  ||| S:974 E:976 ||| .
It  ||| S:976 E:979 ||| PRP
may  ||| S:979 E:983 ||| MD
possess  ||| S:983 E:991 ||| VB
cardiometabolic  ||| S:991 E:1007 ||| JJ
actions  ||| S:1007 E:1015 ||| NNS
with  ||| S:1015 E:1020 ||| IN
the  ||| S:1020 E:1024 ||| DT
potential  ||| S:1024 E:1034 ||| JJ
to  ||| S:1034 E:1037 ||| TO
improve  ||| S:1037 E:1045 ||| VB
the  ||| S:1045 E:1049 ||| DT
cardiovascular  ||| S:1049 E:1064 ||| JJ
risk  ||| S:1064 E:1069 ||| NN
profile  ||| S:1069 E:1077 ||| NN
of  ||| S:1077 E:1080 ||| IN
patients  ||| S:1080 E:1089 ||| NNS
with  ||| S:1089 E:1094 ||| IN
T2DM ||| S:1094 E:1098 ||| CD
.  ||| S:1098 E:1100 ||| .
DPP-4  ||| S:1100 E:1106 ||| NNP
inhibitors  ||| S:1106 E:1117 ||| VBD
such  ||| S:1117 E:1122 ||| JJ
as  ||| S:1122 E:1125 ||| IN
sitagliptin  ||| S:1125 E:1137 ||| NN
and  ||| S:1137 E:1141 ||| CC
saxagliptin  ||| S:1141 E:1153 ||| JJ
increase  ||| S:1153 E:1162 ||| NN
endogenous  ||| S:1162 E:1173 ||| VBD
GLP-1  ||| S:1173 E:1179 ||| CD
concentration  ||| S:1179 E:1193 ||| NN
and  ||| S:1193 E:1197 ||| CC
demonstrate  ||| S:1197 E:1209 ||| VB
incretin-associated  ||| S:1209 E:1229 ||| JJ
glucoregulatory  ||| S:1229 E:1245 ||| JJ
actions  ||| S:1245 E:1253 ||| NNS
in  ||| S:1253 E:1256 ||| IN
patients  ||| S:1256 E:1265 ||| NNS
with  ||| S:1265 E:1270 ||| IN
T2DM ||| S:1270 E:1274 ||| CD
.  ||| S:1274 E:1276 ||| .
DPP-4  ||| S:1276 E:1282 ||| NNP
inhibitors  ||| S:1282 E:1293 ||| NNS
are  ||| S:1293 E:1297 ||| VBP
weight  ||| S:1297 E:1304 ||| NN
neutral ||| S:1304 E:1311 ||| NN
.  ||| S:1311 E:1313 ||| .
A  ||| S:1313 E:1315 ||| DT
growing  ||| S:1315 E:1323 ||| VBG
understanding  ||| S:1323 E:1337 ||| NN
of  ||| S:1337 E:1340 ||| IN
the  ||| S:1340 E:1344 ||| DT
roles  ||| S:1344 E:1350 ||| NNS
of  ||| S:1350 E:1353 ||| IN
incretin  ||| S:1353 E:1362 ||| JJ
hormones  ||| S:1362 E:1371 ||| NNS
in  ||| S:1371 E:1374 ||| IN
T2DM  ||| S:1374 E:1379 ||| NNP
may  ||| S:1379 E:1383 ||| MD
further  ||| S:1383 E:1391 ||| RB
clarify  ||| S:1391 E:1399 ||| VB
the  ||| S:1399 E:1403 ||| DT
application  ||| S:1403 E:1415 ||| NN
of  ||| S:1415 E:1418 ||| IN
incretin-based  ||| S:1418 E:1433 ||| JJ
treatment  ||| S:1433 E:1443 ||| NN
strategies ||| S:1443 E:1453 ||| NNS
.  ||| S:1453 E:1455 ||| .
